Find out all about your favorite commercial!

Advertisers

Advertisers of the Opdivo TV Spot, 'Most Prescribed Immunotherapy'

Opdivo TV commercial - Most Prescribed Immunotherapy
Opdivo

IntroductionOpdivo is a brand name for the drug nivolumab, which is a type of immunotherapy used to treat certain types of cancer. It is manufactured by Bristol-Myers Squibb and was first approved by...

What the Opdivo TV commercial - Most Prescribed Immunotherapy is about.

Opdivo TV commercial - Most Prescribed Immunotherapy

Title: Opdivo TV Spot: Unlocking the Power of Immunotherapy

Introduction:In the world of medical advancements, breakthroughs in treatments bring hope. Opdivo, an immunotherapy drug, has garnered significant attention and has been hailed as one of the most prescribed immunotherapy treatments available. In its TV spot, Opdivo showcases the immense potential of immunotherapy in revolutionizing cancer treatment and transforming lives. Let's dive deeper into this captivating TV commercial and explore the remarkable impact of Opdivo.

The Power of Immunotherapy:Opdivo's TV spot begins by highlighting the groundbreaking nature of immunotherapy. It explains how this cutting-edge treatment enhances the body's immune system to fight against cancer cells. Immunotherapy, unlike traditional treatments, targets the underlying causes of cancer, providing patients with new hope.

Real-Life Stories:The commercial proceeds to showcase the compelling stories of individuals who have experienced the transformative effects of Opdivo firsthand. Their journeys, depicted through emotional visuals and uplifting narratives, captivate viewers and offer a glimpse into the life-changing impact of this immunotherapy drug.

Close-ups of vibrant, joyous faces give a sense of immense relief and hope. Each story featured emphasizes the diversity of patients who have benefited from this groundbreaking treatment, thus illustrating its efficacy and wide-reaching impact.

Expert Testimonials:The TV spot further solidifies Opdivo's credibility by incorporating testimonies from medical professionals. Renowned oncologists and researchers speak about the extensive research and significant advancements made in the field of immunotherapy. Their expert opinions lend credibility to the efficacy and safety of Opdivo, solidifying its position as a leading immunotherapy treatment.

The Call to Action:Towards the end of the TV spot, viewers are urged to have conversations with their doctors about Opdivo and its potential role in their treatment plans. The commercial emphasizes the importance of exploring immunotherapy as a viable option for patients seeking a more targeted and effective approach to battling cancer.

Conclusion:Opdivo's TV spot, aptly titled "Most Prescribed Immunotherapy," serves as a powerful testament to the remarkable impact of immunotherapy on cancer treatment. Through touching stories, expert testimonials, and an appeal to viewers to seek further information, the commercial effectively communicates the potential of Opdivo and encourages patients to explore this transformative treatment option.

Disclaimer: This content is for informational purposes only and should not be considered medical advice. Please consult your healthcare professional for personalized treatment options.

Opdivo TV commercial - Most Prescribed Immunotherapy produced for Opdivo was first shown on television on May 15, 2016.

Frequently Asked Questions about opdivo tv spot, 'most prescribed immunotherapy'

For patients receiving Opdivo plus Opdualag, the 12-, 24- and 36-month progression-free survival rates were 48%, 38% and 31%, respectively. Overall survival rates were 77%, 62% and 54%, at these time points, respectively, with a 48-month overall survival rate of 52%.

OPDIVO® (nivolumab) is a prescription medicine used to treat adults and children 12 years of age and older with a type of skin cancer called melanoma to help prevent melanoma from coming back after it and lymph nodes that contain cancer have been removed by surgery.

Keytruda® is marketed by Merck & Co. and Opdivo® is marketed by Bristol Myers Squibb. The drugs are similar in terms of their safety and effectiveness; their key differences relate to their dosing frequency, the drugs they are used in combination with and the types of cancer they are approved for treating.

Nivolumab is a medication used to manage and treat metastatic melanoma and several other tumors. It is a monoclonal antibody that targets the anti-PD1 receptor, an immune checkpoint.

Immunotherapy is a lung cancer treatment. It does not cure stage 4 lung cancer, but it may help patients live longer. Stage 4 lung cancer (also called metastatic lung cancer) is lung cancer that has spread (metastasized) to other parts of the body outside the lungs, such as the brain, bones, and liver.

For patients with advanced non–small cell lung cancer treated with frontline immunotherapy without disease progression at 2 years, real-world data suggest that it is reasonable to discontinue immunotherapy because of the comparable overall survival rates found for patients who continue immunotherapy beyond 2 years.

Opdivo is now indicated for use in the European Union as a monotherapy for the adjuvant treatment of adults and adolescents 12 years of age and older with stage IIB or IIC melanoma, or melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.

Can immunotherapy cure stage 4 cancer? While immunotherapy doesn't cure stage 4 cancer, it can improve the quality and longevity of your life.

Naked monoclonal antibodies are the most common type used in cancer treatment. They're called naked because they're unattached to anything. These antibodies boost your immune system's response against the cancer, or block antigens that help the cancer grow and spread.

First, we compared pembrolizumab to nivolumab in patients with recurrent or advanced NSCLC. The survival analysis showed that pembrolizumab had a better ORR than nivolumab, but no significant difference in PFS was found between pembrolizumab and nivolumab.

Nivolumab improves survival in 80% of trial participants with common lung cancer.

Background: A standard of care for pretreated, advanced non-small-cell lung cancers (NSCLCs), nivolumab has demonstrated long-term benefit when administered for 2 years.

Videos

Watch Opdivo TV Commercial, 'Most Prescribed Immunotherapy'

We analyzed TV commercials placed on popular platforms and found the most relevant videos for you:

Products

Products Advertised

Opdivo
TV commercials

Similar commercials

2018 Volkswagen Atlas TV Spot, 'Parents' [T1]
BarkBox TV Spot, 'Holiday Box'
998 November 30, 2014
Opdivo + Yervoy TV Spot, 'A Chance for More Sparks'
Opdivo + Yervoy TV Spot, 'A Chance to Live Longer'
Opdivo + Yervoy TV Spot, 'A Chance for More Sparks: Live Longer'
Kohl's TV Spot, 'Mamá modelo' canción de Crooked Man
Neulasta Onpro TV Spot, 'The Day After Chemo: Copay Card'
Opdivo + Yervoy TV Spot, 'A Chance for More Horizons'
Neulasta Onpro TV Spot, 'Rather Be Home - Onpro'
Priceline.com TV Spot, 'When Family's on the Line'
Twix Bites TV Spot, 'Walkman' Song by Billy Ocean
Neulasta Onpro TV Spot, 'The Day After Chemo'